HCV direct-acting antiviral agents: the best interferon-free combinations

• Type of Material: Article
• Authors: Raymond Schinazi, Emory University; Philippe Halfon, Hôpital Europeen and Laboratoire Alphabio Marseille; Patrick Marcellin, University Paris Diderot 7 and INSERM U773; Tarik Asselah, University Paris Diderot 7 and INSERM U773
• Language: English
• Date: 2014-02-01
• Publisher: WILEY
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: 2014
• Final Published Version (URL): http://dx.doi.org/10.1111/liv.12423
• Title of Journal or Parent Work: LIVER INTERNATIONAL
• Volume: 34
• Issue: SUPPL1
• Start Page: 69
• End Page: 78
• Grant/Funding Information: This work was supported in part by CFAR NIH grant 2P30AI-050409 (to RFS) and by the Department of Veterans Affairs (to RFS). We thank Judy Mathew and Steve Coats for proofing this manuscript. Dr. Schinazi is the founder and a major shareholder of RFS Pharma, LLC.
• Keywords: ribavirin; TELAPREVIR; PROGRESSION; HEPATITIS; BILN-2061; SOFOSBUVIR; simeprevir; faldaprevir; asunaprevir; Life Sciences & Biomedicine; Science & Technology; Gastroenterology & Hepatology; sofosbuvir; RESISTANCE; FALDAPREVIR; RIBAVIRIN; daclatasvir; PEGYLATED INTERFERON; pegylated interferon; PROTEASE INHIBITOR
• Research Categories: Health Sciences, General; Engineering, Biomedical

Abstract

For HCV infection, there have been major advancements during last several years with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency, favourable tolerability profile, higher barrier to resistance, shortened treatment duration, all oral regimen, pan-genotypic, fewer drug interactions and reduced pill burden. By 2014, several DAAs are anticipated to complete successful phase III trials and will be commercially available. Initially, a wave of IFN-based regimen (sofosbuvir, faldaprevir and simeprevir) will be available for treatment of HCV genotype 1. In the near future, combination of antiviral agents with additive potency that lack cross-resistance with good safety profile will likely be the new recommended regimens, making HCV, the first chronic viral infection to be eradicated worldwide with a finite duration of combination DAA therapy without IFN or ribavirin. The aim of this review was to summarize the results obtained from recent DAA combination studies without IFN. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.